Background

Malignant mesothelioma, associated with asbestos or erionite exposure, is an aggressive and lethal cancer of the mesothelium, the protective lining that covers many internal organs of the body, most commonly found in the pleura (outer lining of the lungs).

Technology Overview

The inventors discovered that misregulation of a protein called High Mobility Group Box 1 (HMBG1) is linked to mesothelioma in subjects exposed to asbestos. HMGB1 is a member of the high-mobility group protein super-family that plays important roles in biological processes like transcription, DNA repair, proliferation and inflammation. After asbestos and erionite exposure, HMGB1 is released by mesothelial cells undergoing programmed cell necrosis, initiating inflammatory processes and promoting tumor growth (Yang et al., 2010, Jube et al., 2012).

Utilizing a mouse model of malignant mesothelioma, the inventors discovered HMGB1 to be a highly sensitive biomarker for early detection of mesothelioma, and proposed a number of therapeutic strategies of inhibiting HMGB1 and methods for prevention of mesothelioma caused by asbestos exposure.

Further Details:

Napolitano et al., 2016. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clinical Cancer Research, 22(12): 3087‑3096.
Jube et al., 2012. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Research, 72(13):3290-3301.
Yang et al., 2010. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA, 107:12611-12616.

Benefits

Proposed biomarker for early detection of mesothelioma and asbestos exposure

Applications

Detection of mesothelioma
Detection of asbestos exposure

Mesothelioma Biomarker

Patents

IP Status

Seeking